Publication:

CCR7 Is Critical for the Induction and Maintenance of Th17 Immunity in Dry Eye Disease

Loading...
Thumbnail Image

Date

2014

Published Version

Journal Title

Journal ISSN

Volume Title

Publisher

Association for Research in Vision and Ophthalmology (ARVO)
The Harvard community has made this article openly available. Please share how this access benefits you.

Research Projects

Organizational Units

Journal Issue

Citation

Kodati, Shilpa, Sunil K. Chauhan, Yihe Chen, Thomas H. Dohlman, Parisa Karimian, Daniel Saban, and Reza Dana. 2014. “CCR7 Is Critical for the Induction and Maintenance of Th17 Immunity in Dry Eye Disease.” Investigative Opthalmology & Visual Science 55 (9) (September 18): 5871. doi:10.1167/iovs.14-14481.

Abstract

Purpose.

We characterized antigen-presenting cell (APC)–relevant chemokine receptor expression in dry eye disease (DED), and investigated the effect of topical CC chemokine receptor (CCR)-7 blockade specifically on Th17 cell immunity and dry eye disease severity.

Methods.

We induced DED in female C57BL/6 mice. Chemokine receptor expression by corneal APCs was characterized using immunohistochemistry. To determine the functional role of CCR7 in DED, mice were treated topically with either anti-CCR7, a control isotype antibody, or left untreated, and clinical disease severity, Th17 responses, and molecular markers of DED were quantified.

Results.

Frequencies of CD11b+ cells and their chemokine expression were increased in the cornea of DED mice. Mice treated topically with anti-CCR7 antibody displayed a significant reduction in clinical disease severity and Th17 response compared to the isotype and untreated groups. Topical CCR7 blockade was effective in ameliorating DED in its acute and chronic stages.

Conclusions.

Our findings suggest that CCR7-mediated trafficking of APCs drives the induction and maintenance of Th17 immunity in DED and that CCR7 blockade is effective in suppressing the immunopathogenic mechanisms in DED.

Description

Research Data

Keywords

Terms of Use

This article is made available under the terms and conditions applicable to Other Posted Material (LAA), as set forth at Terms of Service

Endorsement

Review

Supplemented By

Related Stories